Jpmorgan Chase & CO Verona Pharma PLC Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VRNA
# of Institutions
166Shares Held
68.7MCall Options Held
704KPut Options Held
685K-
Perceptive Advisors LLC New York, NY6.32MShares$245 Million4.75% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$217 Million12.27% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.01MShares$194 Million2.01% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx4.22MShares$164 Million2.52% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$138 Million14.95% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $2.37B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...